Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)
Autore:
Shibayama, T; Ueoka, H; Nishii, K; Kiura, K; Tabata, M; Miyatake, K; Kitajima, T; Harada, M;
Indirizzi:
AntiTB Assoc, Okayama Branch, Okayama 7000952, Japan AntiTB Assoc Okayama Japan 7000952 kayama Branch, Okayama 7000952, Japan Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan OkayamaUniv Okayama Japan 7008558 nternal Med 2, Okayama 7008558, Japan
Titolo Testata:
LUNG CANCER
fascicolo: 1, volume: 32, anno: 2001,
pagine: 61 - 69
SICI:
0169-5002(200104)32:1<61:CROPP(>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-MARKER; HORMONE PRODUCTION; CARCINOMA;
Keywords:
pro-gastrin-releasing peptide (ProGRP); neuron specific enolase (NSE); small-cell lung cancer; diagnosis; prognostic factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Shibayama, T AntiTB Assoc, Okayama Branch, 408-1 Hirata, Okayama 7000952, Japan AntiTB Assoc 408-1 Hirata Okayama Japan 7000952 00952, Japan
Citazione:
T. Shibayama et al., "Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)", LUNG CANC, 32(1), 2001, pp. 61-69

Abstract

In this study, we evaluated the clinical usefulness of ProGRP and NSE for diagnosis and prognosis of small-cell lung cancer (SCLC). Serum levels of ProGRP and NSE were determined in 108 healthy subjects, 103 patients with benign pulmonary diseases, 142 with non-small cell lung cancer (NSCLC), and 114 with SCLC. Sensitivity of ProGRP in diagnosis of SCLC was significantly higher than that of NSE (64.9 vs. 43.0%, P < 0.001). The difference was substantial in patients with limited disease (56.5 vs. 20.3%, P < 0.001). However, 11 of 40 SCLC patients with normal levels of serum ProGRP (27.5%) showed elevated levels of serum NSE. In the SCLC patients receiving chemotherapy, the CR rate in patients with elevated NSE levels was significantly lowerthan in patients with normal levels of NSE (18.5 vs. 61.7%, P < 0.001). Elevation of both ProGRP and NSE was a poor prognostic factor, and patients with elevated levels of either ProGRP or NSE showed shorter survival than those without. From multivariate analysis, NSE was found to have a greater effect on survival of SCLC patients than ProGRP. These findings indicate thatProGRP is more sensitive than NSE for diagnosis of SCLC, while NSE is superior to ProGRP as a prognostic factor. In conclusion, both ProGRP and NSE an useful tumor markers and they have a complementary role for each other indiagnosis and prognosis of SCLC. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 04:53:29